1996 –Initial public offering on NASDAQ under ticker symbol ALXN. 1998 –First in-human clinical trial of eculizumab begins, 2000 –Corporate headquarters relocated to Cheshire, CT, USA. 2002 –Pilot study with eculizumab commenced in Leeds, England in paroxysmal nocturnal hemoglobinuria (PNH). ...